Evaluation of pancreatic tissue penetration of Meronem® in the prophylaxis of septic complications in severe pancreatitis
Study identifier:3591/9010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Evaluation of pancreatic tissue penetration of Meronem® in the prophylaxis of septic complications in severe pancreatitis
Medical condition
Pancreatitis
Phase
Phase 4
Healthy volunteers
No
Study drug
Meropenem
Sex
All
Actual Enrollment
6
Study type
Interventional
Age
N/A
Date
Study Start Date: 01 Feb 2002
Primary Completion Date: 01 Sept 2005
Study Completion Date: 01 May 2007
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2008 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Columbia Medical Director
AstraZeneca
